Closed-loop Spinal Stimulation for Restoration of Upper Extremity Function After Spinal Cord Injury
Purpose
The purpose of this study is to assess the efficacy of non-invasive (transcutaneous) closed-loop electrical spinal cord stimulation for recovery of upper limb function (Aim 1) and spasticity (Aim 2) following spinal cord injury.
Condition
- Spinal Cord Injuries
Eligibility
- Eligible Ages
- Between 21 Years and 70 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- has cervical (C8 or higher), incomplete (American Spinal Cord Injury Impairment Scale - C or D) traumatic spinal cord injury, minimum 1-year post-injury 2. has difficulty with hand functions in activities of daily living (e.g., dressing, grooming, feeding) 3. stable medical condition without cardiopulmonary disease or autonomic dysreflexia that would contraindicate participation in upper extremity rehabilitation or testing activities 4. capable of performing simple cued motor tasks 5. has ability to attend intervention/functional task training and assessment sessions 3 times/week 6. has adequate social support to participate in all intervention and baseline/follow-up assessment sessions throughout 40 weeks. 7. has ability to read and speak English
Exclusion Criteria
- dependent on ventilation support 2. has implanted stimulator (e.g., pacemaker, vagus nerve stimulator, cochlear implant, etc.) or baclofen pump 3. has metallic devices and implants in the head (e.g., deep brain stimulators, aneurysm clips/coils, and stents, vagus nerve stimulators) 4. has a history or current signs/symptoms of syringomyelia (progressive pain, muscle weakness, and/or sensory loss; deterioration of bowel/bladder function) 5. has autoimmune etiology of spinal cord dysfunction/injury 6. has received botulinum toxin injections in upper extremity muscles in the prior 6 months 7. has tendon transfer or nerve transfer surgery in the upper extremity, 8. taking tizanidine, dantrolene or diazepam 9. has history of seizures or increased risk for seizures 10. has history of chronic headaches or migraines 11. has history of neurologic diseases, such as stroke, multiple sclerosis, traumatic brain injury, etc. 12. has peripheral neuropathy (diabetic polyneuropathy, entrapment neuropathy, etc.) 13. has rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.) 14. has significant medical disease; including uncontrolled systemic hypertension with values above 170/100 mmHg; cardiac or pulmonary disease; uncorrected coagulation abnormalities or need for therapeutic anticoagulation 15. has cardiovascular or musculoskeletal disease or injury that would prevent full participation in physical therapy intervention 16. unhealed fracture, contracture, pressure sore, or frequent urinary tract infections or other illnesses that might interfere with upper extremity rehabilitation or testing activities 17. has a history of severe allergy (i.e., allergic reaction that could not be treated with antihistaminic medication 18. has alcohol and/or drug abuse (subject's verbal statement) 19. has cancer 20. pregnant (Childbearing potential will be asked at screening, baseline, and every subsequent visit in which the subject would receive transcutaneous spinal cord stimulation and/or Transcranial Magnetic Stimulation whether the participant could be pregnant. Pregnancy will be ruled out by an over-the-counter urine pregnancy test for all females of childbearing potential (1) at the time of enrollment, (2) prior to all sessions that include Transcranial Magnetic Stimulation, and also prior to the intervention phases of (3) closed-loop or (4) open-loop stimulation. Additional pregnancy tests may be performed if there is a concern of pregnancy.) 21. lack of ability to fully comprehend, cooperate and/or safely perform study procedures in the investigator's opinion/judgment 22. unable to read and/or comprehend the consent form
Study Design
- Phase
- N/A
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover Assignment
- Intervention Model Description
- Participants who participate in Aim 1 Section of the study will receive open-loop and closed-loop stimulation intervention arms in a randomized order. The order of the two interventions in the Aim 2 Section of the study will be the same for all participants enrolled in the Aim 2 Section of the study.
- Primary Purpose
- Treatment
- Masking
- Single (Outcomes Assessor)
- Masking Description
- Functional measurements and all other assessments will be done by an examiner who does not know the order of the intervention arm.
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Open-loop Stimulation |
Continuous stimulation |
|
|
Experimental Close-loop Stimulation |
Intended movement-based stimulation. |
|
Recruiting Locations
Seattle, Washington 98195
More Details
- NCT ID
- NCT05267951
- Status
- Recruiting
- Sponsor
- University of Washington
Detailed Description
After being informed about the purpose, study timeline, and procedures, all participants giving written informed consent will undergo repeated baseline measurements throughout four weeks, followed by intensive exercise therapy for six weeks. Next, participants will receive (1) closed-loop stimulation and (2) open-loop stimulation treatment for Aim 1 Section of the study. Stimulation will be delivered non-invasively using skin electrodes on the back of the neck. Each treatment arm will last six weeks. The investigators will determine the order of the treatment arms randomly. For closed-loop stimulation, The investigators will place a sensor on the arm muscles over the skin. This sensor will detect the movement and start the stimulation accordingly. For Aim 2 Section, intervention arms will consist of (1) transcutaneous stimulation, followed by (2) spasticity-reducing stimulation treatment arms. There will be a 6-week waiting period between two stimulation arms where participants will not receive any stimulation or exercise therapy. Treatments will last 90 minutes per session, three sessions per week. Overall participation in the study will last ten months: Four weeks baseline + three treatment periods (each will last six weeks) + six weeks waiting period between stimulation treatments + 12 weeks follow-up.